Cargando…
Lomitapide: a review of its clinical use, efficacy, and tolerability
Lomitapide is an inhibitor of MTP, an enzyme located in the endoplasmic reticulum of hepatocytes and enterocytes. This enzyme is responsible for the synthesis of very low-density lipoproteins in the liver and chylomicrons in the intestine. Lomitapide has been approved by the US Food and Drug Adminis...
Autores principales: | Alonso, Rodrigo, Cuevas, Ada, Mata, Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615460/ https://www.ncbi.nlm.nih.gov/pubmed/31308834 http://dx.doi.org/10.2147/CE.S174169 |
Ejemplares similares
-
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study
por: D’Erasmo, Laura, et al.
Publicado: (2022) -
Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017) -
Xanthomas Regression in an 8-Year-Old Boy Treated With Lomitapide
por: Kolovou, Genovefa, et al.
Publicado: (2019) -
Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites
por: de Sousa, Ana Carolina C., et al.
Publicado: (2020) -
Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022)